FDA and state rules, for what you actually buy.

Must a pharmacy located in another state hold a license/registration from this state to ship prescriptions (including patient-specific 503A compounded preparations) to patients or practitioners here?

Ala. Code §34-23-30 requires every pharmacy, and any entity providing pharmacy services for patients residing in Alabama, to register and hold a Board permit (renewed every two years). It bars any mail order pharmacy from doing business in the state without a permit, and sets separate nonresident permit fees. Ala. Admin. Code r. 680-X-2-.07 bars a nonresident pharmacy from shipping, mailing or delivering prescription drugs to an Alabama patient unless registered. The pharmacy must be in good standing at home, name an Alabama agent for service of process, keep retrievable records, run a toll-free pharmacist line, file a policy and procedure manual, and follow Alabama controlled-substance, substitution and labeling law. Rule 680-X-2-.07(4)(f) requires a supervising pharmacist licensed by the Alabama Board. Separately, §34-23-32(g) bars any pharmacy business in the drug supply chain from shipping legend drugs into Alabama without a valid Board permit ($4,000 civil penalty per violation).

§34-23-30 was most recently amended by Act 2025-372; the specific 2025 change was not reviewed. Rule 680-X-2-.19 (amended effective May 15, 2025) requires pharmacies engaged in sterile compounding to be registered with and certified by the Board as parenteral sterile compounding pharmacies; how the Board applies that certification to nonresident pharmacies was not confirmed. Rule 680-X-2-.07 was last amended effective Jan. 14, 2023.

May a 503A (traditional) pharmacy dispense or distribute compounded preparations to a practitioner for office use (administration in the office, not patient-specific)? The federal position is that 503A requires patient-specific prescriptions; this is what the state pharmacy act and board rules allow.

Ala. Code §34-23-160 allows a pharmacy to prepare a compounded drug product for a prescriber's office use. Conditions: the prescriber's order stating formula and quantity is filed at the pharmacy; the product is administered in the prescriber's office and not dispensed to the patient; and a sale record (prescriber, date, product and amount) is kept at least one year. The label must show name, strength, quantity, compounding date, beyond-use date, lot number, pharmacy name and address, and the phrase 'For Office Use'. §34-23-150 treats distributing 'inordinate amounts' of compounded products without a prescriber/patient/pharmacist relationship as manufacturing. A nonresident pharmacy shipping legend drugs into Alabama must hold a Board permit (§34-23-30; §34-23-32(g)). The statute is broader than FDA's view that 503A compounding must be patient-specific.

The lead that Alabama allows only patient-specific compounded products to be shipped in was NOT confirmed. No such limit was found in Ala. Code ch. 34-23 or in Ala. Admin. Code ch. 680-X-2 (revised 7/13/26), and §34-23-160 applies to 'a pharmacy' without an in-state limit. Check with the Alabama Board of Pharmacy (https://albop.com) before relying on nonresident office-use shipments. Related: per ALBOP, the Alabama Board of Medical Examiners issued a declaratory ruling that physicians compounding GLP-1 products must follow USP standards and 'must purchase prescription products and ingredients only from an entity permitted by ALBOP' (ruling date not shown on the page). §34-23-160 dates to Act 2003-389, amended by Act 2017-422.

Does the state require an FDA-registered 503B outsourcing facility located outside the state to hold a state license/registration (as an outsourcing facility, nonresident manufacturer, wholesaler or pharmacy) before shipping into the state?

Ala. Code §34-23-32(a) requires every outsourcing facility in the drug supply chain to register annually with the Alabama Board of Pharmacy for a permit. §34-23-32(g) bars any outsourcing facility from shipping legend drugs into Alabama without a valid Board permit, with a $4,000 civil penalty per violation. Ala. Admin. Code r. 680-X-2-.23 defines an outsourcing facility by its FDA 503B registration and requires an Alabama-licensed supervising pharmacist for the location (r. 680-X-2-.23(9)(b)). The Board may contract out-of-state inspections to other boards or NABP at the permit holder's cost. The Board's facility application list for 503Bs asks for the most recent unredacted FDA inspection and response, a list of compounds, testing and beyond-use-date policies, and discipline/recall history.

Pending: an Aug. 19, 2026 notice of intended action would amend r. 680-X-2-.23 to raise facility permit fees ($750 to $1,500 initial; $500 to $1,000 renewal) and designated-representative fees, effective mid-January 2027. Comments are due Oct. 20, 2026 and the hearing is Oct. 21, 2026 (https://albop.com/statutes-rules/). Rule .23 was amended effective Dec. 15, 2025, Apr. 13, 2026 and June 14, 2026.

Has the state signed FDA's standard Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products (October 2020)? If not, FD&C Act §503A limits its 503A pharmacies' out-of-state distribution to 5% of total prescription orders (currently not enforced by FDA pending rulemaking).

Signing the standard MOU means the state board agrees to investigate complaints about compounded drugs its 503A pharmacies ship out of state and to identify and report to FDA pharmacies that distribute "inordinate amounts" interstate (more than 50% of their compounded prescriptions); in exchange, the statutory 5% out-of-state cap in FD&C Act §503A(b)(3)(B) does not apply to that state's pharmacies. FDA lists only Colorado, Kentucky and New Hampshire as signatories; Alabama is not among them. For a non-signing state, FD&C Act §503A(b)(3)(B)(ii) caps a 503A pharmacy's out-of-state distribution of compounded drugs at 5% of its total prescription orders. FDA now considers the October 2020 standard MOU suspended (it does not expect signatory states to carry out MOU activities and will not sign new ones) and is not enforcing the 5% limit until a final rule and an updated MOU are published; FDA's rulemaking (RIN 0910-AI71) listed a proposed rule for 11/2026 in the Fall 2025 Unified Agenda.

The FDA list of signed MOUs (current as of 2023-01-23) is older than 2 years, but FDA stopped entering new agreements under the 2020 MOU in October 2022, so no state can have signed since. The FDA "Compounding Information for States" page (current as of 2026-08-28) still describes the MOU as awaiting rulemaking. Pending: FDA proposed rule on 503A distribution (RIN 0910-AI71, NPRM projected 11/2026); H.R. 5316 (introduced 2025-09-11, referred to House Energy & Commerce) would remove the MOU provision from §503A.

Besides DEA registration, does the state require practitioners to hold a separate state controlled substance registration, license or permit to prescribe, administer or dispense controlled substances (e.g. testosterone, Schedule III)? "Conditional" means a state registration is needed only in some settings, such as keeping controlled-substance stock in the office.

Board rule 540-X-4-.01 requires every Alabama-licensed physician who distributes, prescribes or dispenses any controlled substance in Alabama to obtain annually a registration certificate; the fee is $150 (it includes the PDMP fee) and ACSCs renew each year by Dec. 31. The Board's ACSC page tells applicants to apply for the Alabama DEA registration after receiving the ACSC, and an active DEA registration must be maintained; physicians with additional DEA registrations for multiple dispensing sites report those numbers to the Board (one ACSC, not one per site). A physician who dispenses controlled substances for use off the premises (other than manufacturer samples) must also register with the Board as a dispensing physician; drugs administered in the office are not 'dispensed' for that rule. PAs need a Qualified ACSC (QACSC; $110 initial, $60 annual renewal by Jan. 1; the Board page says Schedules III-V) before applying for DEA; CRNPs/CNMs also use a QACSC.

Waived for physicians working exclusively for the VA and for residents during their first 18 months. Per-location: the ACSC is one certificate per physician; DEA registration is per location. In-office administration does not trigger the separate dispensing-physician registration, but dispensing take-home controlled substances (e.g., testosterone for home use) does.

Must a prescriber query the state Prescription Drug Monitoring Program before prescribing, and does the mandate cover Schedule III drugs such as testosterone? "Yes" means a mandate that reaches Schedule III; "conditional" means a mandate limited to certain drugs (e.g. opioids or benzodiazepines) or situations; "no" means no prescriber query mandate.

Board of Medical Examiners rule 540-X-4-.09 requires physicians prescribing more than 30 morphine milligram equivalents (MME) or 3 lorazepam milligram equivalents (LME) per day to review the patient's PDMP history at least twice a year. For prescriptions above 90 MME or 5 LME per day, the physician must query the PDMP every time, on the same day the prescription is written. Below 30 MME/3 LME, PDMP use is expected 'consistent with good clinical practice' but is not mandated. Exemptions cover nursing home patients, hospice patients, active malignant pain and intra-operative care. Enforced by the Alabama Board of Medical Examiners / Medical Licensure Commission.

Source older than 2 years - possibly stale (rule last amended eff. 8/8/2019 per the text read). Rule text read on LII, not on the official Alabama Administrative Code site. PDMP TTAC also lists parallel rules for other boards (e.g., 540-X-12-.18, 540-X-18-.15, 540-X-20-.09) not reviewed here. A separate rule (540-X-25-.10) requires a 24-month PDMP review before certifying a patient for medical cannabis - not relevant to testosterone. Testosterone (C-III) is not caught.

May physicians dispense prescription drugs (not just administer them) directly to patients from their practice? "Yes" means allowed under standard rules (labeling, records, and at most a simple notice to the board); "conditional" means a separate dispensing registration, permit or license, or quantity, day-supply or drug-category limits; "no" means prohibited except narrow exceptions.

The Alabama Board of Medical Examiners requires physicians who order and deliver controlled substances to patients in the office to register as Dispensing Physicians under Rule 540-X-4-.05; there is no fee. Every location where medications are dispensed must be registered with its own DEA number. Prepackaged samples, starter packs and non-controlled legend drugs do not trigger the registration. Physicians who dispense controlled substances must report them to the Alabama PDMP (Department of Public Health). An Alabama Controlled Substances Certificate is also needed to handle controlled substances.

Board page carries no revision date; access date used.

For a patient located in the state: must the prescriber hold this state's license (or a telehealth registration or special license), is an in-person exam required before prescribing (generally or for controlled substances), are there state limits on prescribing Schedule III drugs such as testosterone by telehealth, and is the state an Interstate Medical Licensure Compact member? "Yes" means a state license and the in-person standard of care apply (opioid-only or Schedule II-only limits are described but do not change the answer); "conditional" means extra state conditions such as a telehealth registration route, an in-person exam requirement, controlled-substance limits reaching Schedule III, or registration of telehealth businesses. Federal DEA rules apply on top.

Physicians treating patients in Alabama by telehealth need a full, active Alabama license, except for irregular or infrequent care (under 10 days or 10 patients a year) or consultation with an Alabama physician (Ala. Code 34-24-702). The relationship may be formed without a prior in-person exam, but if the same condition is treated by telehealth more than four times in 12 months without resolution, the patient must be seen in person within 12 months. A controlled substance, including testosterone, may be prescribed by telehealth only with synchronous audio or video, at least one in-person encounter in the preceding 12 months, and a legitimate medical purpose established within that time (on-site licensed staff can satisfy the in-person element). IMLC: member.

CCHP quotes the statute and the Board of Medical Examiners telemedicine page.

Who may administer botulinum toxin and dermal fillers (physicians, PAs, NPs, RNs, LPNs, estheticians, dentists), under what supervision (on-site vs available), and must a physician/NP/PA perform a prior good-faith exam?

In a statement on a petition to let physicians train and delegate cosmetic neuromodulator and filler injections (considered 2024-12-12), the Board said the decision to order, inject and administer these products is the practice of medicine and declined to adopt delegation rules. It said PAs and CRNPs could only gain this skill through future Board-approved practice protocols, and noted dermatology groups' safety evidence for treating fillers separately from neuromodulators. The petitioner described Alabama as the only state where delegated injectors cannot perform cosmetic injections under supervision. The Alabama Board of Nursing argued RNs could inject on a prescriber's order under ABN-approved procedures, but the Medical Board rejected that approach.

Board considered the petition 2024-12-12; the posted file name carries 12.20.2025. The Board reserved the right to write PA/CRNP protocols for botulinum toxin, so watch for changes. The Board of Nursing disagrees with the Medical Board on RN scope.

What does the state require for elective IV hydration/vitamin (incl. NAD+) therapy: who may start IVs, is a patient-specific order or good-faith exam required before a patient's first IV, are standing orders allowed, and are there rules for mobile IV services?

The Board of Medical Examiners' 2022 declaratory ruling on retail IV therapy businesses found that the common model, in which an RN alone evaluates the patient under a physician's standing orders, violates Alabama law on unlicensed practice and dispensing. Businesses must create a physician-patient relationship through an individualized evaluation by a physician, or a PA, CRNP or CNM in a legal collaboration or registration; the evaluation may occur in person or by telemedicine (Ala. Code §34-24-703(b)). The prescriber must diagnose, keep a compliant record and issue a prescription before the IV is given. Businesses may not control practitioners' medical judgment.

Over two years old (possibly stale) but still listed on the Board's practice-issues page on 2026-09-23 and cited by other states' 2023–2025 guidance.

Does the state enforce the corporate practice of medicine doctrine (non-physicians may not own medical practices or employ physicians), and how does that affect med spa ownership?

In October 1992 declaratory rulings, the Board of Medical Examiners and the Medical Licensure Commission held that a business corporation employing a licensed physician is not engaged in unlicensed practice, and the physician is not aiding it, where the corporation exercises no control over how the physician provides medical services or exercises medical judgment. The Board's 2022 IV ruling repeats that businesses may not control practitioners' independent judgment. Permit Health and MedPath both list Alabama as a non-CPOM state.

1992 rulings are old but still posted by the Board; the Board also lists a 2014 opinion on physician employment by LLCs (not read).

Who may perform laser/IPL/RF aesthetic procedures (laser hair removal, resurfacing): physicians only, delegated to RNs/PAs, or licensed electrologists/estheticians/laser technicians with state certification?

Board Rule 540-X-11 treats any laser, light or energy-based device affecting living tissue as the practice of medicine. Ablative resurfacing, laser-assisted liposuction and endovenous ablation are physician-only. Non-ablative treatments (hair removal, IPL/BBL, photorejuvenation, vascular/pigment lesions, tattoo removal, RF/ultrasound/cryolipolysis skin tightening) may be delegated by written protocol to Level 1 delegates (PA, CRNP, RN) or Level 2 delegates (LPN, medical assistant, esthetician, cosmetologist, laser technician) who meet Board education requirements. Supervision must be on site (physician in the same building), except that board-certified physicians with specific training may supervise Level 1 delegates 'locally remotely'. Physicians must register with the Board, sign consent and protocol requirements, and delegates need continuing education and minimum annual procedures.

Page has no date (accessed 2026-09-23). The Board's 2024 statement calls these 'recently passed laser rules'. A 2025 declaratory ruling on red light therapy by non-physicians in med spas is also posted (not reviewed).

Does the state license clinical laboratories itself, beyond federal CLIA certification, including out-of-state labs that test specimens from the state?

Most states rely on federal CLIA certification alone. The states confirmed in this research as issuing their own lab licenses are California, New York, Pennsylvania, Maryland and Rhode Island (which also reach out-of-state labs testing specimens from their residents), plus Nevada, Washington, Massachusetts, New Jersey and New Hampshire (labs located in the state). Alabama was not among them, but this research did not confirm its statutes. Alabama's CLIA state agency is Alabama Dept. of Public Health, Division of Health Care Facilities, CLIA Program (CLIAAlabama@adph.state.al.us, 334-206-5120); it can confirm whether any state license or permit applies, including to out-of-state labs.

Absence of a state license was not verified against the state's statutes or rules.

May consumers order their own lab tests without a practitioner order (direct access testing)? A practitioner-ordered panel is always fine; this matters for take-home and consumer test kits.

ADLM (formerly AACC) reported in 2019 that 37 states and DC let consumers order some or all tests directly, but it did not publish the state list, and this research did not confirm Alabama's rule. Alabama's lab regulator (CLIA state agency) is Alabama Dept. of Public Health, Division of Health Care Facilities, CLIA Program (CLIAAlabama@adph.state.al.us, 334-206-5120). The question matters for take-home and consumer test kits, not for panels a clinician orders.

The ADLM figure dates from 2019 (older than 2 years).

Has the state enacted a law or rule specifically about stem cell, exosome or regenerative-medicine therapies (notice/disclosure duties, permission for certain non-FDA-approved uses, or Right to Try extensions covering them)?

Compilations of state stem-cell laws from 2024 to 2026 list about a dozen states with specific laws (California, Florida, Georgia, Mississippi, Nevada, North Carolina, Tennessee, Texas, Utah, Vermont, Washington and Wyoming), plus Montana's general experimental-treatment law and Kansas's state stem cell center. Alabama is not among them. Without a state-specific law, regenerative products are governed by federal FDA rules plus the state's general medical practice, advertising and consumer-protection laws, enforced by its medical board. Federal FDA rules still apply regardless of state law: stem cell, birth-tissue and exosome products are regulated by FDA, and a state law cannot make an unapproved biologic FDA-approved.

The finding of no law rests on multi-state compilations (a commercial one from Aug 2026 and a peer-reviewed one from Feb 2024, which is older than 2 years) and targeted searches, not a statute-by-statute review, and neither compilation is exhaustive. General Right to Try laws for terminal patients, where they exist, were not reviewed here.

Does the state have cosmetic or sunscreen requirements beyond federal MoCRA, such as ingredient bans (PFAS, formaldehyde, phthalates), ingredient reporting, sunscreen-ingredient bans, or bans on selling animal-tested cosmetics?

Alabama does not appear on 2026 compilations of state PFAS-in-cosmetics laws, on the list of states banning animal-tested cosmetics, or among the jurisdictions with sunscreen-ingredient bans. Federal MoCRA and FDA rules on cosmetics and OTC sunscreens still apply. Other state laws that touch cosmetics generally, such as state food-drug-cosmetic acts or consumer-protection laws, were not surveyed.

The animal-testing list is Wikipedia's 'as of 2023' compilation (older than 2 years); effective dates were not confirmed.